-
Join 37 other subscribers
Categories
Top Posts
Blogroll
Tag Archives: Pharmaceutical industry
Biopharmaceutical Innovation Hubs and the Future of Work
Innovation hubs such as metro Boston are all the rage. Urban living is back in style, face-to-face communication trounces teleconferences, and innovation-starved pharma companies are looking to academic centers for new targets and new enabling technologies. Academic institutions in turn are looking … Continue reading
Posted in Boston-Cambridge, Economics, Innovation
Tagged biotech hub, innovation hub, Pharmaceutical industry
Leave a comment
Bristol Meyers Squibb Joins the R&D Hub Consolidation in Cambridge, Massachusetts
BMS has just announced that it will be closing its Wallingford, Connecticut facility and relocating much of R&D to Cambridge MA. Derek Lowe has some coverage.
Posted in Pharmaceutical Industry
Tagged biotech hub, BMS, innovation hub, Pharmaceutical industry
Leave a comment
China crackdowns squeeze pharma margins
From Reuters: A crackdown on corruption and pricing in China’s fast-growing pharmaceutical market has squeezed profits and margins, raising a red flag to global Big Pharma that the days of easy growth in the country may be over. Over the … Continue reading
Posted in Pharmaceutical Industry
Tagged branded generics, China, Pharmaceutical industry
Leave a comment
Who’s The Best In Drug Research? 22 Companies Ranked Incorrectly
Matt Herper at Forbes has a post on new pharmaceutical research productivity data from Richard Evans, a former Roche executive and Wall Street analyst. Evans calculates metrics such as (1) Economic Returns to R&D spending, (2) Patents / $1M R&D spend, (3) Average … Continue reading
Pfizer is a shark that can’t stop feeding
So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading
Posted in Pharmaceutical Industry
Tagged AstraZeneca, Consolidation, merger, Pfizer, Pharmaceutical industry
Leave a comment
Consolidation in the Pharma industry continues unabated
As large assets swaps, mergers and acquisitions continue in the Pharma industry, Merck has announced it is selling its Consumer Care division to Bayer for $14B. The transaction will move Bayer into second place in consumer care, behind J&J. Merck … Continue reading
Posted in Pharmaceutical Industry
Tagged asset sales, Bayer, Merck, Pharmaceutical industry
Leave a comment
Pharma companies consider selling off mature drug portfolios
As big shifts in the Pharmaceutical industry continue, Reuters is reporting that several large pharma companies, including Abbott, Merck and Sanofi, are considering selling off their portfolios of compounds that have lost patent protection. From a pharma company’s perspective, branded … Continue reading
Pharma megamergers — against the spirit of the times?
Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday. As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading
Posted in Fixing Big Pharma Research, Pharmaceutical Industry
Tagged Eli Lilly, GSK, M&A, megamergers, Novartis, Pfizer, Pharmaceutical industry
1 Comment
Pharma deal frenzy points to fundamental change in strategy
Pharmaceutical giants Novartis and GSK announced a large swap in business units on Tuesday, resulting in both companies becoming significantly more specialized — reversing their decades-long traditional strategies of greater diversification across product lines. The Wall Street Journal has more than … Continue reading
Posted in Pharmaceutical Industry
Tagged Consolidation, GSK, M&A, Novartis, Pharmaceutical industry, Specialization
1 Comment
Infographic: Top 15 Large Pharma Companies by Market Cap
Interesting chart of the top 15 large pharma & biotech firms ranked by market capitalization. Note the resemblance to a power-law distribution (or exponential, really). If business outcomes are distributed like this, why would employee performance be normally distributed? Data from … Continue reading
Posted in Management
Tagged employee performance, market capitalization, Pharmaceutical industry
Leave a comment